Diagnosed with AR and surgery isn’t an option?*
You may be eligible for a clinical trial involving transcatheter aortic valve replacement (TAVR).
University of Washington
in Seattle, WA
Is accepting patients in the ALIGN-AR trial
The ALIGN-AR clinical trial will study transcatheter aortic valve replacement (TAVR) in patients with symptomatic, severe aortic regurgitation (AR) that are at high risk for surgery. In this trial, the JenaValve Trilogy® TAVR System will be used.
Diagnosed with AR and surgery isn’t an option?*
You may be eligible for a clinical trial involving transcatheter aortic valve replacement (TAVR).
Principal Investigator:
James McCabe, MD
University of Washington
ALIGN-AR Trial Location
Seattle, WA 98195
See All ALIGN-AR Trial Site Locations & Contact Information
See the Align-AR patient brochure for more information
*For patients that are at high risk for surgical aortic valve replacement.
Diagnosed with AR and surgery isn’t an option?*
You may be eligible for a clinical trial involving transcatheter aortic valve replacement (TAVR).